Skip to content
OpenCapital
Get started

RenovoRx RNXT Q4 2025 Annual earnings

Reported March 30, 2026 · After market close

Revenue$238.0KMiss by $181.7KDiluted EPS-$0.08In line
Revenue estimate$419.7K
EPS estimate-$0.08

Next report

Aug 13, 2026 (in a month)
Revenue estimate$703.8K
EPS estimate-$0.08

Versus estimates

Revenue

Q1 2026$563.0KBeat by $93.5K
Q4 2025$238.0KMiss by $181.7K
Q3 2025$266.0KMiss by $139.4KQ2 2025$422.0KBeat by $118.0KQ1 2025$197.0KBeat by $13.7KQ4 2024$43.0KMiss by $124.5K

Diluted EPS

Q1 2026-$0.08In line
Q4 2025-$0.08In line
Q3 2025-$0.08In lineQ2 2025-$0.08In lineQ1 2025-$0.08In lineQ4 2024-$0.12Beat by $0.01

Ask the moment RenovoRx reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did RenovoRx report Q4 2025 earnings?
RenovoRx (RNXT) reported Q4 2025 earnings on March 30, 2026 after market close.
What were RenovoRx's Q4 2025 revenue and EPS?
RenovoRx reported revenue of $238.0K and diluted EPS of $-0.08 for Q4 2025.
Did RenovoRx beat estimates in Q4 2025?
Revenue missed the consensus estimate of $419.7K by $181.7K. EPS beat the consensus estimate of $-0.08 by $0.00.
How did RenovoRx's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 453.5% from $43.0K a year earlier and diluted EPS grew 33.3% from $-0.12.
Where can I find RenovoRx's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001493152-26-013080) and the 10-K periodic report (0001193125-26-131928) directly on SEC EDGAR. The filing index links above go to sec.gov.